Research programme: stem cell therapies - Qihan Biotech
Alternative Names: Enhanced allogeneic cell therapies; immunologically privileged allogeneic cellsLatest Information Update: 09 Oct 2020
At a glance
- Originator Qihan Biotech
- Class Antineoplastics; Gene therapies; Immunotherapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer